COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,398 Articles (22,816 medRxiv, 8,582 bioRxiv)

Most recent first Previous |  Page 975: Articles 9741-9750  | Next

Are high urea values before intravenous immunoglobulin replacement a risk factor for COVID-related mortality?
Aytekin, G., ATAYIK, E.
10.1101/2022.01.29.22270080 — Posted: 2022-01-31
Estimating COVID-19 Vaccination Effectiveness Using Electronic Health Records of an Academic Medical Center in Michigan
Roberts, E., Gu, T., Mukherjee, B., Fritsche, L. G.
10.1101/2022.01.29.22269971 — Posted: 2022-01-31
"Populist Attitude and Conspiracist beliefs contribution to the overconfidence about the risk of Covid-19: implications for Preventive Health Behaviors"
Giuliani, A., Presaghi, F.
10.1101/2022.01.30.22269992 — Posted: 2022-01-31
Assessment of Out of Pocket Expenditure and associated factors for availing COVID-19 vaccination by the beneficiaries in Bengaluru: South India
Dodderi, S. K., H, L., J, S., S, M., R S, S.
10.1101/2022.01.29.22270032 — Posted: 2022-01-31
Socio-demographic characteristics and their relation to medical service consumption among elderly in Israel during the COVID-19 lockdown in 2020 compared to the corresponding period in 2019
Shaked, O., Korn, L., Shapira, Y., Zigdon, A.
10.1101/2022.01.29.22269933 — Posted: 2022-01-31
Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection
Shopen, N., Dekel, M., Mizrahi, M., Zandberg, E., Bishouty, N., Talmud, D., Vaknin, B., Haberman, S., Katz Shalhav, M., Zeltser, D., Cohen, N.
10.1101/2022.01.29.22270090 — Posted: 2022-01-31
Breakthrough SARS-CoV-2 infections in MS patients on disease modifying therapies
Schiavetti, I., Cordioli, C., Stromillo, M. L., Ferro, M. T., Laroni, A., Cocco, E., Cola, G., Pasquali, L., Rilla, M. T., Signoriello, E., Iodice, R., Di Sapio, A., Lanzillo, R., Caleri, F., Annovazzi, P., Conte, A., Liberatore, G., Ruscica, F., Docimo, R., Bonavita, S., Ulivelli, M., Cavalla, P., Patti, F., Ferraro, D., Clerico, M., Immovilli, P., Di Filippo, M., Salvetti, M., Sormani, M. P., the "Breakthrough infections in MS" study group
10.1101/2022.01.22.22269630 — Posted: 2022-01-31
Observed serial intervals of SARS-CoV-2 for the Omicron and Delta varaints in Belgium based on contact tracing data, 19 November to 31 December 2021
Kremer, C., Braeye, T., Proesmans, K., Andre, E., Torneri, A., Hens, N.
10.1101/2022.01.28.22269756 — Posted: 2022-01-30
Viral Cultures for Assessing Airborne Transmission of SARS-CoV-2: a Systematic Review Protocol
Heneghan, C. J., Spencer, E. A., Brassey, J., Rosca, E. C., Pluddemann, A., Evans, D. H., Conly, J. M., Maltoni, S., Jefferson, T., ONAKPOYA, I. J.
10.1101/2022.01.28.22270021 — Posted: 2022-01-30
Limit of Detection for Rapid Antigen Testing of the SARS-CoV-2 Omicron Variant
Stanley, S., Hamel, D. J., Wolf, I. D., Riedel, S., Dutta, S., Cheng, A., Kirby, J. E., Kanki, P. J.
10.1101/2022.01.28.22269968 — Posted: 2022-01-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).